.Pharmacolibrary.Drugs.ATC.L.L01FD01 .Pharmacolibrary.Drugs.ATC.L.L01FD01| name: | Trastuzumab |
| ATC code: | L01FD01 | route: | intravenous |
| n-compartments | 2 |
Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2/neu) and is primarily used in the treatment of HER2-positive breast cancer and metastatic gastric cancer. It is an approved therapy used in clinical practice today.
Pharmacokinetic parameters are reported for adult female patients with HER2-positive metastatic breast cancer receiving intravenous trastuzumab. Parameters are for a typical patient as reported in published population pharmacokinetic studies.
Doi, T, et al., & Tamura, K (2017). Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. The Lancet. Oncology 18(11) 1512–1522. DOI:10.1016/S1470-2045(17)30604-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29037983
Tan, AR, et al., & Jackisch, C (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology 22(1) 85–97. DOI:10.1016/S1470-2045(20)30536-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33357420
Ismael, G, et al., & Jackisch, C (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet. Oncology 13(9) 869–878. DOI:10.1016/S1470-2045(12)70329-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22884505